ICCC Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
8.0M
+11.9%
7.2M
-30.6%
10.4M
+35.8%
7.6M
+38.5%
5.5M
Cost of Revenue
4.5M
-5.6%
4.7M
-16.7%
5.7M
+20.9%
4.7M
+50.0%
3.1M
Gross Profit
3.6M
+45.9%
2.4M
-47.7%
4.7M
+60.0%
2.9M
+23.2%
2.4M
Operating Expenses
2.6M
+417.1%
502.3K
-81.3%
2.7M
-9.4%
3.0M
+26.7%
2.3M
R&D
176.8K
+47.7%
119.7K
-62.3%
317.7K
-58.1%
758.9K
+9.3%
694.3K
SG&A
2.4M
+1.6%
2.4M
+0.5%
2.4M
+7.3%
2.2M
+34.0%
1.6M
Operating Income
957.8K
-50.5%
1.9M
-1.7%
2.0M
+3498.0%
-57956
-388.7%
20.1K
EBITDA
1.4M
-41.1%
2.4M
-3.7%
2.5M
+285.2%
648.4K
-7.3%
699.2K
Net Income
952.5K
-48.1%
1.8M
-5.5%
1.9M
+168.1%
-2849142
-1938.8%
-139748
EPS (Basic)
$0.10
-50.0%
$0.20
-4.8%
$0.21
+167.7%
$-0.31
-1450.0%
$-0.02
EPS (Diluted)
$0.10
-50.0%
$0.20
-4.8%
$0.21
+167.7%
$-0.31
-1450.0%
$-0.02
Shares (Diluted)
9.3M
+1.2%
9.2M
+1.6%
9.0M
-0.0%
9.0M
+0.0%
9.0M
Immucell (ICCC) — Financials